Tianeptine is an antidepressant drug approved in several countries within Europe, Latin America, and Asia. The exact molecular mode of action of tianeptine is still not completely understood. Initially, the therapeutic effects of this molecule were attributed to an increase in dopamine and serotonin reuptake. 1 Other studies have found that tianeptine induces modulation of the glutamatergic system. 2 More recently, experimental data suggested that tianeptine also exhibits opiate μ-receptor agonist properties. 3 Previous articles noted that tianeptine use carries a potential for abuse, and can induce a withdrawal syndrome at supratherapeutic doses. 4, 5 The therapeutic use of tianeptine during pregnancy has not raised any safety concerns until now. 6 However, the impact of using tianeptine at supratherapeutic doses during pregnancy has not been previously evaluated. We hereby report the case of 2 successive pregnancies in a context of severe maternal dependence on tianeptine, which led to subsequent neonatal abstinence syndrome in the first neonate. The reported case is described herein according to the CAse REport (CARE) checklist. 7 abstract Tianeptine, an atypical antidepressant, has been found to exhibit a potential for abuse. The use of therapeutic doses of tianeptine during pregnancy has never raised safety concerns. However, the impact of tianeptine abuse on the mother-child dyad has never been assessed. We report herein the case of a female patient who presented with dependence on tianeptine, with the use of >650 mg of the drug per day. She had 2 successive pregnancies with similar doses. The state of dependence remained unidentified throughout the first pregnancy, but just after delivery, her full-term newborn exhibited unexpected neonatal abstinence syndrome (NAS). The NAS was successfully treated with morphine, although both the mother's and newborn's urine drug screen was negative. The causality of tianeptine in inducing NAS was retrospectively assessed as "probable" by using a validated causality algorithm. During the second pregnancy, this patient sought addiction treatment and was admitted for residential detoxification treatment in her seventh month of pregnancy. Delivery occurred at full term with a low birth weight neonate. No further developmental insults or medical problems were subsequently identified in the 2 children. Maternal tianeptine dependence during pregnancy may induce a type of NAS that mimics opiate NAS. This finding appears to be consistent with a recent finding of the agonist action of tianeptine on the opiate μ-receptor. 
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CASE REPORT
Ms X is a 29-year-old female patient with no notable history of physical disorders. She developed tobacco dependence at the age of 12, and currently smokes 30 cigarettes per day (20 pack-years). At the age of 23, she gave birth to her first child, a 1860-g boy born by cesarean delivery at 36 weeks of gestation. The cesarean delivery was chosen because of threatened preterm labor with fetal heart rate abnormalities. Two years later, she experienced her first episode of major depressive disorder, for which tianeptine was introduced (see Fig 1) . Although the depression symptoms disappeared in the following months, her dose of tianeptine slowly increased, and she began practicing doctor shopping to obtain sufficient doses of tianeptine. By 26 years of age, the dose reached approximately 50 tablets (ie, 625 mg) per day. Ms X retrospectively reported that she had already experienced withdrawal symptoms when she had been unable to obtain sufficient amounts of tianeptine.
At the age of 26, Ms X became pregnant again. She was not taking any medications besides tianeptine at that time. She concealed her state of dependence from the physicians who supervised the pregnancy, and no medical problems were reported throughout the prenatal period. Ms X gave birth without complications to a full-term, 3300-g male infant, and she did not breastfeed the newborn. Twenty-four hours after delivery, the child began to display several concurrent symptoms, including high-pitched crying, excessive sucking, poor feeding, regurgitation, sweating, frequent yawning, and sneezing. The first 2 Finnegan scores 8 were ≥12, which led to suspicion of opiate neonatal abstinence syndrome (NAS), although both the mother's and newborn's urinary screen revealed no substance use. As recommended based on the Finnegan scores, 9 morphine syrup was introduced to the newborn and tapered over 5 days, which quickly reduced his symptoms. Thereafter, the child was systematically followed by a maternal and child health service, in accordance with the French recommendations, 10 which were inspired by and are very similar to the American guidelines. 11 No medical problems or developmental abnormalities were reported over the following 2 years. However, the maternal dependence on tianeptine persisted.
At the age of 28, Ms X became pregnant for the third time. After 5 months of pregnancy, she consulted an addiction service with the intent of treating her dependence. At this time, Ms X reported using 56 tablets (ie, 700 mg) of tianeptine per day. She expressed an intense feeling of guilt regarding her medical condition and its possible impact on her child. Thus, she was largely treatment-adherent at that time. A 1-month-long supervised tianeptine dose tapering was proposed in a mother-infant psychiatric unit. The tianeptine dose was tapered by 2 tablets each day. During this process, Ms X reported occasional and moderate withdrawal symptoms (ie, insomnia, anxiety, rhinorrhea, and diarrhea), which were treated with symptomatic drugs (ie, hydroxyzine, paracetamol, and a physiologic salt solution for airway clearance). A complete ultrasound evaluation was performed at the 34th week of gestation. The fetal growth was judged to be appropriate (2022 g, ie, 28th percentile), and the amniotic liquid volume was normal. The child was a girl born by cesarean delivery at full term. She weighed 2685 g. The mother did not breastfeed the newborn. Although only 6 months have passed since birth, no medical problems or developmental abnormalities have been identified in the infant during the systematic follow-up performed by the mother and child health service.
Ms X provided written consent for this case to be published. The entire case described herein was recorded in the French pharmacovigilance database (#LL1401790/ #LL20141790).
DISCUSSION
This case report consists of the first clinical follow-up and description of a state of severe dependence on tianeptine during 2 successive pregnancies and births. Our main finding was that the birth of Ms X's second child was rapidly complicated 2
FIGURE 1
Summary timeline of events (the age of the patient is indicated in abscise). At the age of 25, Ms X received her fi rst tianeptine treatment of a characterized major episode. Although the depression symptoms disappeared in the following months, her dose of tianeptine slowly increased, and she began practicing doctor shopping. By 26 years of age, the dose reached 50 tablets (625 mg) per day. During the entire second pregnancy, she was severely dependent on tianeptine, which remained unnoticed by the medical team. Shortly after the delivery, the child displayed symptoms of NAS, with 2 consecutive Finnegan 8 scores ≥12. Although both the mother's and newborn's urinary screens revealed no substance use, morphine syrup was used to treat the newborn, which quickly reduced his symptoms. During the third pregnancy, the patient spontaneously sought treatment of tianeptine dependence. After careful assessment of the risk-benefi t ratio, a team-based decision was made to carry out progressive dose tapering and to stop tianeptine use before the delivery.
by guest on January 9, 2016 Downloaded from by the occurrence of tianeptine NAS in the newborn. The causality of tianeptine for inducing the NAS was retrospectively assessed with the pediatrician (CA) who cared for the first child. By using the Kramer algorithm, 12 a causality tool for evaluating drug withdrawal, 13 the likelihood of tianeptine being the cause of the NAS was determined to be "probable" (see Table 1 ).
This type of neonatal complication has not been previously described for tianeptine. Probably for this reason, tianeptine NAS was mistaken for an opiate NAS and was successfully treated with morphine syrup, although the maternal urine screening for addictive drugs was negative. The clinical features of tianeptine NAS and the therapeutic effect of morphine should probably be seen in light of the recently found agonist effect of tianeptine on opiate μ-receptors. 3 Similarly, the protracted diarrhea and nasal drip reported by Ms X during her supervised tianeptine withdrawal are also suggestive of some opiatelike withdrawal symptoms induced by tianeptine tapering. Previous experimental and clinical data support this hypothesis (eg, the fact that the μ-receptor antagonist naloxone was able to effectively treat tianeptine poisoning 14 and that tianeptine reduces opiate withdrawal effects induced by naloxone in morphine-dependent rats). 15 Overall, except for NAS, no developmental or gestational effects induced by chronic exposure to high doses of tianeptine were identified in the 2 children at the time of this case report. This result is in line with previous reports of the use of therapeutic doses of tianeptine during pregnancy, which has never been associated with teratogenicity or pejorative fetal outcomes until now. 16 Moreover, the progressive and supervised tianeptine dose tapering in Ms X during her second pregnancy was associated with only slight withdrawal symptoms that required the use of symptomatic medications. We acknowledge that the decision to progressively stop tianeptine use by the patient before delivery was made because of the important psychological distress that resulted from the patient's dependence. However, in practice, these decisions should be made on a case-by-case basis, after careful assessment of the risk-benefit ratio.
In conclusion, herein, we reported the first case of a tianeptine-related opiatelike NAS in a newborn, after severe tianeptine dependence in the mother during pregnancy. Tianeptine withdrawal has already been reported in adult subjects with tianeptine dependence 4,5 but never previously in a newborn. The causal role of tianeptine in triggering NAS was assessed and found "probable" by using a validated causality algorithm. Nevertheless, the singlecase nature of this report may limit the conclusions that can be drawn, and it should essentially serve as a safety warning for clinicians. 17 Finally, morphine syrup appeared to be efficacious for treating the NAS, which provides additional clinical support for the agonist action of tianeptine on the opiate μ-receptor. 
+1
-the tianeptine-NAS association is not so unusual as to prevent knowing what timing to expect for an ADR of this type -the timing was consistent with a substance NAS -given the type of ADR, the timing and the context were not only consistent with, but as expected for an ADR to tianeptine Axis 4. Drug levels and evidence of withdrawal -NAS is a dose-related manifestation +1
-no measure of tianeptine was available in serum, urine, or other body fl uid -due to the delivery, there is unequivocal evidence that the kinetics of tianeptine in the newborn was consistent with a withdrawal process Axis 5. Drug reinstitution -absence of reinstitution of tianeptine in the newborn 0 -administration of morphine syrup with rapid improvement of the NAS Axis 6. Second episode of drug discontinuation -no other episode of tianeptine discontinuation in the newborn 0 Total Score +4
The algorithm questions were adapted for drug withdrawal according to the instructions given by Kramer et al. 12 The fi nal "+4" score means that the causality of tianeptine for inducing the NAS is "probable." ADR, adverse drug reaction.
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